Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Seizures × Temozolomide × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 154 Brain Neoplasms 73 Glioma 69 Central Nervous System Neoplasms 50 Gliosarcoma 46 Astrocytoma 37 Melanoma 36 Oligodendroglioma 29 Neuroblastoma 17 Neoplasm Metastasis 14 Carcinoma, Non-Small-Cell Lung 12 Lung Neoplasms 11 Sarcoma, Ewing 10 Sarcoma 10 Neoplasms 10 Medulloblastoma 10 Recurrence 9 Neuroendocrine Tumors 9 Lymphoma 8 Ependymoma 8 Breast Neoplasms 8 Small Cell Lung Carcinoma 7 Rhabdomyosarcoma 7 Diffuse Intrinsic Pontine Glioma 7 Colorectal Neoplasms 7 Ovarian Neoplasms 6 Carcinoma, Neuroendocrine 6 Adenoma, Islet Cell 6 Uveal Melanoma 5 Spinal Cord Neoplasms 5

Interventions

Levetiracetam 2 Temozolomide 1 Standard of Care 1 Pregabalin 1 Medical Marijuana 1 Drug Therapy 1 Aspirin 1 Anticonvulsants 1 Anastrozole 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04450160 2020-06-29

AEO

MetVital, Inc.

Phase 2 Unknown

Glioblastoma, Seizures

Data powered by HemOnc (CC BY 4.0) Colophon ⚡